|
1
|
National Cancer Institute. Pancreatic
Cancer-National Cancer Institute, U.S. National Institutes of
Health. Cancer. https://www.cancer.gov/types/pancreatic.
Accessed 06-04-2010
|
|
2
|
Maitra A and Hruban RH: Pancreatic cancer.
Annu Rev Pathol. 3:157–188. 2008. View Article : Google Scholar
|
|
3
|
Li D, Xie K, Wolff R and Abbruzzese JL:
Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mulcahy MF, Wahl AO and Small W Jr: The
current status of combined radiotherapy and chemotherapy for
locally advanced or resected pancreas cancer. J Natl Compr Canc
Netw. 3:637–642. 2005.PubMed/NCBI
|
|
5
|
Pino SM, Xiong HQ, McConkey D and
Abbruzzese JL: Novel therapies for pancreatic adenocarcinoma. Curr
Oncol Rep. 6:199–206. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vaccaro V, Sperduti I and Milella M:
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N
Engl J Med. 365:768–769; author reply 769. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pestka JJ, Yike I, Dearborn DG, Ward MD
and Harkema JR: Stachybotrys chartarum, trichothecene mycotoxins,
and damp building-related illness: New insights into a public
health enigma. Toxicol Sci. 104:4–26. 2008. View Article : Google Scholar
|
|
8
|
Hossain MA, Ahmed MS and Ghannoum MA:
Attributes of Stachybotrys chartarum and its association with human
disease. J Allergy Clin Immunol. 113:200–208; quiz 209. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kilburn KH: Role of molds and mycotoxins
in being sick in buildings: Neurobehavioral and pulmonary
impairment. Adv Appl Microbiol. 55:339–359. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hardin BD, Kelman BJ and Saxon A: Adverse
human health effects associated with molds in the indoor
environment. J Occup Environ Med. 45:470–478. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Leatherman DL and Middlebrook JL: Effect
of emetine on T-2 toxin-induced inhibition of protein synthesis in
mammalian cells. J Pharmacol Exp Ther. 266:741–748. 1993.PubMed/NCBI
|
|
12
|
Ge HM, Jiao RH, Zhang YF, Zhang J, Wang YR
and Tan RX: Cytotoxicity and phytotoxicity of trichothecene
macrolides from Myrothecium gramminum. Planta Med. 75:227–229.
2009. View Article : Google Scholar
|
|
13
|
Abbas HK, Johnson BB, Shier WT, Tak H,
Jarvis BB and Boyette CD: Phytotoxicity and mammalian cytotoxicity
of macrocyclic trichothecene mycotoxins from Myrothecium
verrucaria. Phytochemistry. 59:309–313. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shifrin VI and Anderson P: Trichothecene
mycotoxins trigger a ribotoxic stress response that activates c-Jun
N-terminal kinase and p38 mitogen-activated protein kinase and
induces apoptosis. J Biol Chem. 274:13985–13992. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chung YJ, Jarvis B and Pestka J:
Modulation of lipopolysaccharide-induced proinflammatory cytokine
production by satratoxins and other macrocyclic trichothecenes in
the murine macrophage. J Toxicol Environ Health A. 66:379–391.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hughes BJ, Taylor MJ and Sharma RP:
Effects of verrucarin A and roridin A, macrocyclic trichothecene
mycotoxins, on the murine immune system. Immunopharmacology.
16:79–87. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Palanivel K, Kanimozhi V and Kadalmani B:
Verrucarin A alters cell-cycle regulatory proteins and induces
apoptosis through reactive oxygen species-dependent p38MAPK
activation in the human breast cancer cell line MCF-7. Tumour Biol.
35:10159–10167. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Palanivel K, Kanimozhi V, Kadalmani B and
Akbarsha MA: Verrucarin A induces apoptosis through ROS-mediated
EGFR/MAPK/Akt signaling pathways in MDA-MB-231 breast cancer cells.
J Cell Biochem. 115:2022–2032. 2014.PubMed/NCBI
|
|
19
|
Woldemichael GM, Turbyville TJ, Vasselli
JR, Linehan WM and McMahon JB: Lack of a functional VHL gene
product sensitizes renal cell carcinoma cells to the apoptotic
effects of the protein synthesis inhibitor verrucarin A. Neoplasia.
14:771–777. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang GH, Jarvis BB, Chung YJ and Pestka
JJ: Apoptosis induction by the satratoxins and other trichothecene
mycotoxins: Relationship to ERK, p38 MAPK, and SAPK/JNK activation.
Toxicol Appl Pharmacol. 164:149–160. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Amagata T, Rath C, Rigot JF, Tarlov N,
Tenney K, Valeriote FA and Crews P: Structures and cytotoxic
properties of trichoverroids and their macrolide analogues produced
by saltwater culture of Myrothecium verrucaria. J Med Chem.
46:4342–4350. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chin YW, Balunas MJ, Chai HB and Kinghorn
AD: Drug discovery from natural sources. AAPS J. 8:E239–E253. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Itokawa H, Morris-Natschke SL, Akiyama T
and Lee KH: Plant-derived natural product research aimed at new
drug discovery. J Nat Med. 62:263–280. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kerr JF, Winterford CM and Harmon BV:
Apoptosis. Its significance in cancer and cancer therapy. Cancer.
73:2013–2026. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cusack JC Jr: Overcoming antiapoptotic
responses to promote chemosensitivity in metastatic colorectal
cancer to the liver. Ann Surg Oncol. 10:852–862. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ramanathan B, Jan KY, Chen CH, Hour TC, Yu
HJ and Pu YS: Resistance to paclitaxel is proportional to cellular
total antioxidant capacity. Cancer Res. 65:8455–8460. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sun Y and Rigas B: The thioredoxin system
mediates redox-induced cell death in human colon cancer cells:
Implications for the mechanism of action of anticancer agents.
Cancer Res. 68:8269–8277. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chao DT and Korsmeyer SJ: BCL-2 family:
Regulators of cell death. Annu Rev Immunol. 16:395–419. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Green DR and Reed JC: Mitochondria and
apoptosis. Science. 281:1309–1312. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Deveraux QL and Reed JC: IAP family
proteins - suppressors of apoptosis. Genes Dev. 13:239–252. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Altomare DA and Testa JR: Perturbations of
the AKT signaling pathway in human cancer. Oncogene. 24:7455–7464.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Datta SR, Dudek H, Tao X, Masters S, Fu H,
Gotoh Y and Greenberg ME: Akt phosphorylation of BAD couples
survival signals to the cell-intrinsic death machinery. Cell.
91:231–241. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo
P, Hu LS, Anderson MJ, Arden KC, Blenis J and Greenberg ME: Akt
promotes cell survival by phosphorylating and inhibiting a Forkhead
transcription factor. Cell. 96:857–868. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mayo MW and Baldwin AS: The transcription
factor NF-kappaB: Control of oncogenesis and cancer therapy
resistance. Biochim Biophys Acta. 1470:M55–M62. 2000.PubMed/NCBI
|
|
36
|
Bjornsti MA and Houghton PJ: The TOR
pathway: A target for cancer therapy. Nat Rev Cancer. 4:335–348.
2004. View
Article : Google Scholar : PubMed/NCBI
|
